Aerami Therapeutics today announced positive data supporting its inhaled imatinib for treating pulmonary hypertension (PH).
Studies of AER-901 support progression into a Phase 2 clinical trial. Data backed Aerami’s treatment for both PH associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
AER-901 is a drug-device combination. Aerami designed it to deliver potentially reverse-remodeling imatinib therapy deeply and efficiently throughout diseased tissue of the lung. Delivery takes place through a high-performance, handheld, smart nebulizer. It controls flow rates and provides patients with real-time feedback to optimize lung deposition.
Get the full story at our sister site, Drug Delivery Business News.